55828 Federal Register / Vol. 75, No. 177 / Tuesday, September 14, 2010 / Notices 

respond, including through the use of 

appropriate automated, electronic, 

mechanical, or other technological 

collection techniques or other forms 

of information technology, e.g., 

permitting electronic submission of 

responses. 

Overview of This Information 

Collection 

(1) Type of Information Collection: 

Extension of a Currently Approved 

Collection. 

(2) Title of the Form/Collection: 

Certification of Identity. 

(3) Agency form number, if any, and 

the applicable component of the 

Department of Justice sponsoring the 

collection: Form DOJ–361. Facilities and 

Administrative Services Staff, Justice 

Management Division, U.S. Department 

of Justice. 

(4) Affected public who will be asked 

or required to respond, as well as a brief 

abstract: Primary: American Citizens. 

Other: Federal Government. The 

information collection will be used by 

the Department to identify individuals 

requesting certain records under the 

Privacy Act. Without this form an 

individual cannot obtain the 

information requested. 

(5) An estimate of the total number of 

respondents and the amount of time 

estimated for an average respondent to 

respond: It is estimated that 27,000 

respondents will complete the form 

within approximately 30 minutes. 

(6) An estimate of the total burden (in 

hours) associated with the collection: 

There are an estimated 13,500 annual 

burden hours associated with this 

collection. 

If Additional Information is Required 

Contact: Lynn Murray, Department 

Clearance Officer, United States 

Department of Justice, Policy and 

Planning Staff, Justice Management 

Division, Suite 1600, Patrick Henry 

Building, 601 D Street, NW., 

Washington, DC 20530. 

Dated: September 8, 2010. 

Lynn Murray, 

Department Clearance Officer, PRA, United 

States Department of Justice. 

[FR Doc. 2010–22888 Filed 9–13–10; 8:45 am] 

BILLING CODE 4410–CW–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

[Docket No. DEA–318F] 

Controlled Substances: Final Revised 

Aggregate Production Quotas for 2010 

AGENCY: Drug Enforcement 

Administration (DEA), Justice. 

ACTION: Notice of final aggregate 

production quotas for 2010. 

SUMMARY: This notice establishes final 

2010 aggregate production quotas for 

controlled substances in schedules I and 

II of the Controlled Substances Act 

(CSA). DEA has taken into consideration 

comments received in response to a 

notice of the proposed revised aggregate 

production quotas for 2010 published 

June 23, 2010 (75 FR 35838). 

DATES: Effective Date: September 14, 

2010. 

FOR FURTHER INFORMATION CONTACT: 

Christine A. Sannerud, Ph.D., Chief, 

Drug and Chemical Evaluation Section, 

Drug Enforcement Administration, 8701 

Morrissette Drive, Springfield, VA 

22152, Telephone: (202) 307–7183. 

SUPPLEMENTARY INFORMATION: Section 

306 of the CSA (21 U.S.C. 826) requires 

that the Attorney General establish 

aggregate production quotas for each 

basic class of controlled substance listed 

in schedules I and II. This responsibility 

has been delegated to the Administrator 

of the DEA by 28 CFR 0.100. The 

Administrator, in turn, has redelegated 

this function to the Deputy 

Administrator, pursuant 28 CFR 0.104. 

The 2010 aggregate production quotas 

represent those quantities of controlled 

substances in schedules I and II that 

may be produced in the United States in 

2010 to provide adequate supplies of 

each substance for: The estimated 

medical, scientific, research and 

industrial needs of the United States; 

lawful export requirements; and the 

establishment and maintenance of 

reserve stocks (21 U.S.C. 826(a) and 21 

CFR 1303.11). These quotas do not 

include imports of controlled 

substances. 

On June 23, 2010, a notice of the 

proposed revised 2010 aggregate 

production quotas for certain controlled 

substances in schedules I and II was 

published in the Federal Register (75 

FR 35838). All interested persons were 

invited to comment on or object to these 

proposed aggregate production quotas 

on or before July 23, 2010. 

Fourteen companies, thirteen DEA 

registered manufacturers and one nonregistrant, commented on a total of 28 

schedules I and II controlled substances 

within the published comment period. 

Comments received proposed that the 

aggregate production quotas for 

alfentanil, amphetamine (for 

conversion), amphetamine (for sale), 

codeine (for conversion), codeine (for 

sale), dextropropoxyphene, 

dihydromorphine, diphenoxylate, 

gamma hydroxybutyric acid, 

hydrocodone, hydromorphone, 

lisdexamfetamine, meperidine, 

methadone, methylphenidate, morphine 

(for conversion), morphine (for sale), 

nabilone, opium (tincture), oxycodone 

(for conversion), oxycodone (for sale), 

oxymorphone (for sale), remifentanil, 

sufentanil, tapentadol, 

tetrahydrocannabinols, thebaine and 

tilidine were insufficient to provide for 

the estimated medical, scientific, 

research, and industrial needs of the 

United States, for export requirements 

and for the establishment and 

maintenance of reserve stocks. 

DEA has taken into consideration the 

above comments along with the relevant 

2009 year-end inventories, initial 2010 

manufacturing quotas, 2010 export 

requirements, actual and projected 2010 

sales, research, product development 

requirements and additional 

applications received. Based on this 

information, the DEA has adjusted the 

final 2010 aggregate production quotas 

for alfentanil, amphetamine (for 

conversion), amphetamine (for sale), 

carfentanil, dihydromorphine, 

diphenoxylate, marihuana, morphine 

(for sale), noroxymorphone (for sale), 

opium (tincture), oxycodone (for 

conversion), oxycodone (for sale), 

oxymorphone (for conversion), 

oxymorphone (for sale), tapentadol, 

tetrahydrocannabinols, and tilidine. 

4-anilino-N-phenethyl-4-piperidine 

(ANPP) pursuant to DEA’s final rule 

published in the Federal Register on 

June 29, 2010 (75 FR 37295) will be 

controlled as a schedule II controlled 

substance on August 30, 2010. As such, 

DEA has established an aggregate 

production quota for ANPP to meet the 

estimated medical, scientific, research, 

and industrial needs of the United 

States; lawful export requirements; and 

the establishment and maintenance of 

reserve stocks. 

Regarding codeine (for conversion), 

codeine (for sale), dextropropoxyphene, 

gamma hydroxybutyric acid, 

hydrocodone, hydromorphone, 

lisdexamfetamine, meperidine, 

methadone, methylphenidate, morphine 

(for conversion), nabilone, remifentanil, 

sufentanil, and thebaine, DEA has 

determined that the proposed revised 

2010 aggregate production quotas are 

sufficient to meet the current 2010 

estimated medical, scientific, research, 

and industrial needs of the United 

States and to provide for adequate 

inventories. 

Therefore, under the authority vested 

in the Attorney General by Section 306 

of the CSA (21 U.S.C. 826), and 

delegated to the Administrator of the 

DEA by 28 CFR 0.100, and redelegated 

to the Deputy Administrator, pursuant 

to 28 CFR 0.104, the Deputy 


jlentini on DSKJ8SOYB1PROD with NOTICES
Federal Register / Vol. 75, No. 177 / Tuesday, September 14, 2010 / Notices 55829 

Administrator hereby orders that the 

2010 final aggregate production quotas 

for the following controlled substances, 

expressed in grams of anhydrous acid or 

base, be established as follows: 

Basic class Final revised 

2010 quotas 

Schedule I 

2,5-Dimethoxyamphetamine .......................................................................................................................................................... 2 g 

2,5-Dimethoxy-4-ethylamphetamine (DOET) ................................................................................................................................ 2 g 

3-Methylfentanyl ............................................................................................................................................................................. 2 g 

3-Methylthiofentanyl ....................................................................................................................................................................... 2 g 

3,4-Methylenedioxyamphetamine (MDA) ...................................................................................................................................... 20 g 

3,4-Methylenedioxy-N-ethylamphetamine (MDEA) ....................................................................................................................... 10 g 

3,4-Methylenedioxymethamphetamine (MDMA) ........................................................................................................................... 20 g 

3,4,5-Trimethoxyamphetamine ...................................................................................................................................................... 2 g 

4-Bromo-2,5-dimethoxyamphetamine (DOB) ................................................................................................................................ 2 g 

4-Bromo-2,5-dimethoxyphenethylamine (2-CB) ............................................................................................................................ 2 g 

4-Methoxyamphetamine ................................................................................................................................................................ 77 g 

4-Methylaminorex .......................................................................................................................................................................... 2 g 

4-Methyl-2,5-dimethoxyamphetamine (DOM) ................................................................................................................................ 2 g 

5-Methoxy-3,4-methylenedioxyamphetamine ................................................................................................................................ 2 g 

Acetyl-alpha-methylfentanyl ........................................................................................................................................................... 2 g 

Acetyldihydrocodeine ..................................................................................................................................................................... 2 g 

Acetylmethadol .............................................................................................................................................................................. 2 g 

Allylprodine .................................................................................................................................................................................... 2 g 

Alphacetylmethadol ........................................................................................................................................................................ 2 g 

Alpha-ethyltryptamine .................................................................................................................................................................... 2 g 

Alphameprodine ............................................................................................................................................................................. 2 g 

Alphamethadol ............................................................................................................................................................................... 2 g 

Alpha-methylfentanyl ..................................................................................................................................................................... 2 g 

Alpha-methylthiofentanyl ................................................................................................................................................................ 2 g 

Alpha-methyltryptamine (AMT) ...................................................................................................................................................... 2 g 

Aminorex ........................................................................................................................................................................................ 2 g 

Benzylmorphine ............................................................................................................................................................................. 2 g 

Betacetylmethadol ......................................................................................................................................................................... 2 g 

Beta-hydroxy-3-methylfentanyl ...................................................................................................................................................... 2 g 

Beta-hydroxyfentanyl ..................................................................................................................................................................... 2 g 

Betameprodine ............................................................................................................................................................................... 2 g 

Betamethadol ................................................................................................................................................................................. 2 g 

Betaprodine .................................................................................................................................................................................... 2 g 

Bufotenine ...................................................................................................................................................................................... 3 g 

Cathinone ....................................................................................................................................................................................... 3 g 

Codeine-N-oxide ............................................................................................................................................................................ 602 g 

Diethyltryptamine ........................................................................................................................................................................... 2 g 

Difenoxin ........................................................................................................................................................................................ 3,000 g 

Dihydromorphine ............................................................................................................................................................................ 3,608,000 g 

Dimethyltryptamine ........................................................................................................................................................................ 3 g 

Gamma-hydroxybutyric acid .......................................................................................................................................................... 52,156,000 g 

Heroin ............................................................................................................................................................................................ 20 g 

Hydromorphinol .............................................................................................................................................................................. 2 g 

Hydroxypethidine ........................................................................................................................................................................... 2 g 

Ibogaine ......................................................................................................................................................................................... 1 g 

Lysergic acid diethylamide (LSD) .................................................................................................................................................. 15 g 

Marihuana ...................................................................................................................................................................................... 21,000 g 

Mescaline ....................................................................................................................................................................................... 5 g 

Methaqualone ................................................................................................................................................................................ 7 g 

Methcathinone ............................................................................................................................................................................... 4 g 

Methyldihydromorphine .................................................................................................................................................................. 2 g 

Morphine-N-oxide .......................................................................................................................................................................... 605 g 

N-Benzylpiperazine ........................................................................................................................................................................ 2 g 

N,N-Dimethylamphetamine ............................................................................................................................................................ 2 g 

N-Ethylamphetamine ..................................................................................................................................................................... 2 g 

N-Hydroxy-3,4-methylenedioxyamphetamine ................................................................................................................................ 2 g 

Noracymethadol ............................................................................................................................................................................. 2 g 

Norlevorphanol ............................................................................................................................................................................... 52 g 

Normethadone ............................................................................................................................................................................... 2 g 

Normorphine .................................................................................................................................................................................. 16 g 

Para-fluorofentanyl ......................................................................................................................................................................... 2 g 

Phenomorphan .............................................................................................................................................................................. 2 g 

Pholcodine ..................................................................................................................................................................................... 2 g 

Psilocybin ....................................................................................................................................................................................... 2 g 

Psilocyn .......................................................................................................................................................................................... 2 g 

Tetrahydrocannabinols .................................................................................................................................................................. 264,000 g 

Thiofentanyl ................................................................................................................................................................................... 2 g 


jlentini on DSKJ8SOYB1PROD with NOTICES
55830 Federal Register / Vol. 75, No. 177 / Tuesday, September 14, 2010 / Notices 

Basic class Final revised 

2010 quotas 

Tilidine ............................................................................................................................................................................................ 10 g 

Trimeperidine ................................................................................................................................................................................. 2 g 

Schedule II 

1-Phenylcyclohexylamine .............................................................................................................................................................. 2 g 

4-anilino-N-phenethyl-4-piperidine (ANPP) ................................................................................................................................... 1,100,000 g 

Alfentanil ........................................................................................................................................................................................ 8,000 g 

Alphaprodine .................................................................................................................................................................................. 2 g 

Amobarbital .................................................................................................................................................................................... 3 g 

Amphetamine (for conversion) ...................................................................................................................................................... 7,500,000 g 

Amphetamine (for sale) ................................................................................................................................................................. 18,600,000 g 

Carfentanil ...................................................................................................................................................................................... 200 g 

Cocaine .......................................................................................................................................................................................... 247,000 g 

Codeine (for conversion) ............................................................................................................................................................... 65,000,000 g 

Codeine (for sale) .......................................................................................................................................................................... 39,605,000 g 

Dextropropoxyphene ...................................................................................................................................................................... 92,000,000 g 

Dihydrocodeine .............................................................................................................................................................................. 800,000 g 

Diphenoxylate ................................................................................................................................................................................ 827,000 g 

Ecgonine ........................................................................................................................................................................................ 83,000 g 

Ethylmorphine ................................................................................................................................................................................ 2 g 

Fentanyl ......................................................................................................................................................................................... 1,428,000 g 

Glutethimide ................................................................................................................................................................................... 2 g 

Hydrocodone .................................................................................................................................................................................. 55,000,000 g 

Hydromorphone ............................................................................................................................................................................. 3,455,000 g 

Isomethadone ................................................................................................................................................................................ 11 g 

Levo-alphacetylmethadol (LAAM) .................................................................................................................................................. 3 g 

Levomethorphan ............................................................................................................................................................................ 5 g 

Levorphanol ................................................................................................................................................................................... 10,000 g 

Lisdexamfetamine .......................................................................................................................................................................... 9,000,000 g 

Meperidine ..................................................................................................................................................................................... 6,600,000 g 

Meperidine Intermediate-A ............................................................................................................................................................ 3 g 

Meperidine Intermediate-B ............................................................................................................................................................ 7 g 

Meperidine Intermediate-C ............................................................................................................................................................ 3 g 

Metazocine ..................................................................................................................................................................................... 1 g 

Methadone ..................................................................................................................................................................................... 20,000,000 g 

Methadone Intermediate ................................................................................................................................................................ 26,000,000 g 

Methamphetamine ......................................................................................................................................................................... 3,130,000 g 

750,000 g of levo-desoxyephedrine for use in a non-controlled, non-prescription product; 2,331,000 g for methamphetamine (for conversion) 

mostly for conversion to a schedule III product; and 49,000 g for methamphetamine (for sale) 

Methylphenidate ............................................................................................................................................................................. 50,000,000 g 

Morphine (for conversion) .............................................................................................................................................................. 83,000,000 g 

Morphine (for sale) ........................................................................................................................................................................ 39,000,000 g 

Nabilone ......................................................................................................................................................................................... 9,002 g 

Noroxymorphone (for conversion) ................................................................................................................................................. 9,000,000 g 

Noroxymorphone (for sale) ............................................................................................................................................................ 41,000 g 

Opium (powder) ............................................................................................................................................................................. 230,000 g 

Opium (tincture) ............................................................................................................................................................................. 1,500,000 g 

Oripavine ........................................................................................................................................................................................ 15,000,000 g 

Oxycodone (for conversion) .......................................................................................................................................................... 5,600,000 g 

Oxycodone (for sale) ..................................................................................................................................................................... 105,500,000 g 

Oxymorphone (for conversion) ...................................................................................................................................................... 12,800,000 g 

Oxymorphone (for sale) ................................................................................................................................................................. 3,070,000 g 

Pentobarbital .................................................................................................................................................................................. 28,000,000 g 

Phenazocine .................................................................................................................................................................................. 1 g 

Phencyclidine ................................................................................................................................................................................. 14 g 

Phenmetrazine ............................................................................................................................................................................... 2 g 

Phenylacetone ............................................................................................................................................................................... 12,500,001 g 

Racemethorphan ........................................................................................................................................................................... 2 g 

Remifentanil ................................................................................................................................................................................... 2,500 g 

Secobarbital ................................................................................................................................................................................... 67,000 g 

Sufentanil ....................................................................................................................................................................................... 7,000 g 

Tapentadol ..................................................................................................................................................................................... 1,000,000 g 

Thebaine ........................................................................................................................................................................................ 126,000,000 g 

The Deputy Administrator further 

orders that the aggregate production 

quotas for all other schedule I and II 

controlled substances included in 21 

CFR 1308.11 and 1308.12 shall be zero. 

The Office of Management and Budget 

has determined that notices of aggregate 

production quotas are not subject to 


jlentini on DSKJ8SOYB1PROD with NOTICES
Federal Register / Vol. 75, No. 177 / Tuesday, September 14, 2010 / Notices 55831 

centralized review under Executive 

Order 12866. 

This action does not preempt or 

modify any provision of state law; nor 

does it impose enforcement 

responsibilities on any state; nor does it 

diminish the power of any state to 

enforce its own laws. Accordingly, this 

action does not have federalism 

implications warranting the application 

of Executive Order 13132. 

The Deputy Administrator hereby 

certifies that this action will have no 

significant impact upon small entities 

whose interests must be considered 

under the Regulatory Flexibility Act, 5 

U.S.C. 601 et seq. The establishment of 

aggregate production quotas for 

schedules I and II controlled substances 

is mandated by law and by international 

treaty obligations. The quotas are 

necessary to provide for the estimated 

medical, scientific, research and 

industrial needs of the United States, for 

export requirements and the 

establishment and maintenance of 

reserve stocks. While aggregate 

production quotas are of primary 

importance to large manufacturers, their 

impact upon small entities is neither 

negative nor beneficial. Accordingly, the 

Deputy Administrator has determined 

that this action does not require a 

regulatory flexibility analysis. 

This action meets the applicable 

standards set forth in Sections 3(a) and 

3(b)(2) of Executive Order 12988 Civil 

Justice Reform. 

This action will not result in the 

expenditure by state, local, and tribal 

governments, in the aggregate, or by the 

private sector, of $126,400,000 or more 

in any one year, and will not 

significantly or uniquely affect small 

governments. Therefore, no actions were 

deemed necessary under the provisions 

of the Unfunded Mandates Reform Act 

of 1995. 

This action is not a major rule as 

defined by Section 804 of the Small 

Business Regulatory Enforcement 

Fairness Act of 1996. This action will 

not result in an annual effect on the 

economy of $100,000,000 or more; a 

major increase in costs or prices; or 

significant adverse effects on 

competition, employment, investment, 

productivity, innovation, or on the 

ability of United States-based 

companies to compete with foreignbased companies in domestic and 

export markets. 

Dated: September 2, 2010. 

Michele M. Leonhart, 

Deputy Administrator. 

[FR Doc. 2010–22785 Filed 9–13–10; 8:45 am] 

BILLING CODE 4410–09–P 

OFFICE OF NATIONAL DRUG 

CONTROL POLICY 

Appointment of Members of Senior 

Executive Services Performance 

Review Board. 

AGENCY: Office of National Drug Control 

Policy [ONDCP]. 

ACTION: Notice of Appointments. 

Heading: Appointment of Members of 

Senior Executive Services Performance 

Review Board. 

SUMMARY: The following persons have 

been appointed to the ONDCP Senior 

Executive Service Performance Review 

Board: Dr. Terry Zobeck, Ms. Martha 

Gagne, Ms. Christine Leonard, and Mr. 

Patrick Ward. 

FOR FURTHER INFORMATION CONTACT: 

Please direct any questions to Linda V. 

Priebe, Deputy General Counsel (202) 

395–6622, Office of National Drug 

Control Policy, Executive Office of the 

President, Washington, DC 20503. 

Linda V. Priebe, 

Deputy General Counsel. 

[FR Doc. 2010–22794 Filed 9–13–10; 8:45 am] 

BILLING CODE 3180–02–P 

NUCLEAR REGULATORY 

COMMISSION 

Advisory Committee on the Medical 

Uses of Isotopes: Call for Nominations 

AGENCY: U.S. Nuclear Regulatory 

Commission. 

ACTION: Call for Nominations. 

SUMMARY: The U.S. Nuclear Regulatory 

Commission (NRC) is advertising for 

nominations for the patients’ rights 

advocate position on the Advisory 

Committee on the Medical Uses of 

Isotopes (ACMUI). Nominees should 

have professional or personal 

experience with or knowledge about 

patient advocacy. Also, involvement or 

leadership with patient advocacy 

organizations is preferred. 

DATES: Nominations are due on or 

before November 15, 2010. 

NOMINATION PROCESS: Submit an 

electronic copy of resume or curriculum 

vitae, along with a cover letter, to Ms. 

Ashley Cockerham, ashley.

cockerham@nrc.gov. The cover letter 

should describe the nominee’s current 

involvement with patients’ rights 

advocacy and express the nominee’s 

interest in the position. Please ensure 

that resume or curriculum vitae 

includes the following information, if 

applicable: education; certification; 

professional association membership 

and committee membership activities; 

and number of years, recentness, and 

type of setting for patient advocacy. 

FOR FURTHER INFORMATION CONTACT: Ms. 

Ashley Cockerham, U.S. Nuclear 

Regulatory Commission, Office of 

Federal and State Materials and 

Environmental Management Programs; 

(240) 888–7129; ashley.cockerham@nrc.

gov. 

SUPPLEMENTARY INFORMATION: The 

patients’ rights advocate provides 

advice to NRC staff on patients’ issues 

associated with the regulation of 

medical applications of byproduct 

material. This advice includes ensuring 

patients’ rights are represented during 

the development and implementation of 

NRC medical-use policy. This 

individual is appointed based on his or 

her professional and personal 

experience with and/or knowledge 

about patient advocacy, involvement 

and/or leadership with patient advocacy 

organizations, and other information 

obtained in letters or during the 

selection process. Nominees should 

have the demonstrated ability to 

establish effective work relationships 

with peers and implement successful 

approaches to problem solving and 

conflict resolution. ACMUI members 

currently serve a four-year term and 

may be considered for reappointment to 

an additional term. The current 

membership is comprised of the 

following professionals: (a) Nuclear 

medicine physician; (b) nuclear 

cardiologist; (c) nuclear medicine 

physicist; (d) therapy medical physicist; 

(e) radiation safety officer; (f) nuclear 

pharmacist; (g) two radiation 

oncologists; (h) patients’ rights 

advocate; (i) Food and Drug 

Administration representative; (j) 

Agreement State representative; (k) 

health care administrator; and (l) 

diagnostic radiologist. For additional 

information about membership on the 

ACMUI, visit the ACMUI Membership 

Web page, http://www.nrc.gov/aboutnrc/regulatory/advisory/acmui/

membership.html. 

Nominees must be U.S. citizens and 

be able to devote approximately 160 

hours per year to Committee business. 

Members are expected to attend semiannual meetings in Rockville, Maryland 

and to participate in teleconferences, as 

needed. Members who are not Federal 

employees are compensated for their 

service. In addition, these members are 

reimbursed for travel and 

correspondence expenses. Full-time 

Federal employees are reimbursed for 

travel expenses only. 

Security Background Check: The 

selected nominee will undergo a 


jlentini on DSKJ8SOYB1PROD with NOTICES